This company listing is no longer active
Albireo Pharma Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-18.1%
Tasa de crecimiento de los beneficios
-3.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 49.3% |
| Rentabilidad financiera | -131.1% |
| Margen neto | -228.5% |
| Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Desglose de ingresos y gastos
Cómo gana y gasta dinero Albireo Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 22 | 57 | -131 | 80 | 87 |
| 30 Jun 22 | 51 | -36 | 77 | 85 |
| 31 Mar 22 | 45 | -33 | 72 | 83 |
| 31 Dec 21 | 41 | -34 | 71 | 81 |
| 30 Sep 21 | 11 | -48 | 65 | 81 |
| 30 Jun 21 | 9 | -136 | 59 | 82 |
| 31 Mar 21 | 9 | -120 | 51 | 79 |
| 31 Dec 20 | 8 | -108 | 44 | 76 |
| 30 Sep 20 | 12 | -90 | 35 | 70 |
| 30 Jun 20 | 11 | -82 | 30 | 60 |
| 31 Mar 20 | 11 | -78 | 27 | 53 |
| 31 Dec 19 | 10 | -63 | 24 | 45 |
| 30 Sep 19 | 4 | -71 | 23 | 41 |
| 30 Jun 19 | 3 | -63 | 21 | 38 |
| 31 Mar 19 | 2 | -61 | 20 | 34 |
| 31 Dec 18 | 13 | -46 | 18 | 31 |
| 30 Sep 18 | 12 | -35 | 17 | 26 |
| 30 Jun 18 | 12 | -28 | 17 | 19 |
| 31 Mar 18 | 11 | -19 | 17 | 16 |
| 31 Dec 17 | 0 | -24 | 16 | 13 |
| 30 Sep 17 | 3 | -31 | 16 | 10 |
| 30 Jun 17 | 3 | -28 | 13 | 9 |
| 31 Mar 17 | 11 | -20 | 12 | 9 |
| 31 Dec 16 | 11 | -16 | 10 | 8 |
| 30 Sep 16 | 13 | -5 | 8 | 8 |
| 30 Jun 16 | 13 | -4 | 8 | 7 |
| 31 Mar 16 | 5 | -8 | 5 | 6 |
Ingresos de calidad: ALBO is currently unprofitable.
Margen de beneficios creciente: ALBO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Acelerando crecimiento: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Rentabilidad financiera
Alta ROE: ALBO has a negative Return on Equity (-131.05%), as it is currently unprofitable.